• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Yuko Yoshikawa and others partake in a communal fitness session outdoors in Tokyo.
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Patient Perspectives

Coping with eye disease and fading vision late in life

Groups of people doing communal exercises are an everyday sight in Japan, but for one woman they are a very public way to show she is fighting back.

Oct 11, 2017

Yuko Yoshikawa feared she could no longer help organize the popular sessions, known as radio exercises, when she began suffering from age-related macular degeneration (AMD), which causes progressive loss of vision in the elderly. The disease results in gradual blurring of the eye’s central vision, making it harder to read and recognize faces, and often triggering depression and feelings of isolation. 

She gained information and support from other patients, and is now working with them to spread the word through a group called AMD Tomonokai, which means “friends” in Japanese. Ms. Yoshikawa, now 65, was encouraged to maintain her involvement with the exercise classes, though she now wears dark glasses to protect her eyes against bright sunlight.

Yuko Yoshikawa has a eye disease and shelters her eyes from the sun in Tokyo.
Ms. Yoshikawa shelters her eyes from the sun in Tokyo.

Through its newsletters, meetings and website, the group shares AMD patients’ experiences and advises them on a range of practical matters, such as how to get the most out of medical consultations, find the best form of therapy, and manage the costs of healthcare. It also offers practical tips, like using a smartphone to read bus timetables by photographing the small print and enlarging it on the screen. Above all, the group stresses the importance of social interaction and maintaining normal activities for as much as possible to counteract the psychological effects of the disease.

Ms. Yoshikawa navigating a staircase at a historic shrine.
Ms. Yoshikawa visits a historic shrine near her Tokyo home.

About 170 million people are affected

The challenges associated with AMD will likely grow as the world’s population ages. In Japan, which has the oldest average population of any country in the world, an estimated 700 000 people suffer from the disease. Worldwide, about 170 million people are affected, and this number is expected to increase to nearly 200 million by 2020. 

Members of AMD Tomonokai find different ways to cope with the disease. Despite her deteriorating vision, Hiroko Ayabe, a 71-year-old retired teacher, continues to play an active role in family life by looking after her grandchildren every day until her daughter and son-in-law get home from work.

The group’s founder and head, Hideo Takahashi, sets a good example by cycling to a small inner-city farm where he and his wife, Chizuko, tend the vegetables they grow – his eyes also protected by dark glasses. Mr. Takahashi, now 68 years old, discovered he had AMD seven years ago and experienced the same uncertainty and isolation as many other patients. However, after a lifetime in the pharmaceutical industry, he was more familiar with the world of healthcare and determined to put his knowledge to good use.

Woman carrying child with eye bandage off airplane
Access to Healthcare

Sight savers jet to the rescue

Hideo Takahashi and his wife stand in front of their vegetable plot.
Hideo Takahashi, founder and head of the AMD support group, with his wife Chizuko at their vegetable plot in Saitama, near Tokyo, Japan.

The group he established now has around 100 members and provides an important source of advice, as well as support and encouragement for patients. And like the plants he tends on his vegetable plot, Mr. Takahashi is confident that now that it has taken root, it will flourish and grow over time.

 

Shareline

Fighting back against age-related macular degeneration takes more than one person – it takes a whole group
Tweet Tweetpopo
Tags: 
Disease Awareness, Eye Care, Living With Disease, Ophthalmology, Eye Disorders
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Couple looking a digital devices outside
Patient Perspectives

Digital innovation looks set to dominate the 2021 healthcare agenda

A woman, accompanied by her caregiver, shares her experiences with a doctor.
Patient Perspectives

Turning the sound up on patient voices in lung cancer research and development

Chinese family embracing exercise and the outdoors
Patient Perspectives

AI Nurse evolving for health failure patients in China

You are here

  1. Home ›
  2. Stories ›
  3. Patient Perspectives

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.